These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism. Pathania D; Millard M; Neamati N Adv Drug Deliv Rev; 2009 Nov; 61(14):1250-75. PubMed ID: 19716393 [TBL] [Abstract][Full Text] [Related]
3. Targeting mitochondrial permeability in cancer drug development. Berridge MV; Herst PM; Lawen A Mol Nutr Food Res; 2009 Jan; 53(1):76-86. PubMed ID: 19035550 [TBL] [Abstract][Full Text] [Related]
4. Targeting cancer stem cells for more effective therapies: Taking out cancer's locomotive engine. Winquist RJ; Boucher DM; Wood M; Furey BF Biochem Pharmacol; 2009 Aug; 78(4):326-34. PubMed ID: 19539800 [TBL] [Abstract][Full Text] [Related]
5. New targets for cancer chemotherapy. Murgo AJ; Dancey J; Eckhardt SG; Hidalgo M; Arbuck SG; Zerivitz K; Blaylock BA Cancer Chemother Biol Response Modif; 2002; 20():239-72. PubMed ID: 12703208 [No Abstract] [Full Text] [Related]
6. Mitochondria as therapeutic targets for cancer chemotherapy. Galluzzi L; Larochette N; Zamzami N; Kroemer G Oncogene; 2006 Aug; 25(34):4812-30. PubMed ID: 16892093 [TBL] [Abstract][Full Text] [Related]
7. Redox-sensitive signaling factors as a novel molecular targets for cancer therapy. Pennington JD; Wang TJ; Nguyen P; Sun L; Bisht K; Smart D; Gius D Drug Resist Updat; 2005 Oct; 8(5):322-30. PubMed ID: 16230045 [TBL] [Abstract][Full Text] [Related]
8. [Systemic and cellular pathways of anti-tumor action of plant adaptogenes]. Arushanian EB Vopr Onkol; 2009; 55(1):15-23. PubMed ID: 19435193 [No Abstract] [Full Text] [Related]
9. [Drug resistance mediated by survival- and growth-promoting signaling pathways]. Fujita N Gan To Kagaku Ryoho; 2009 Apr; 36(4):567-71. PubMed ID: 19381028 [TBL] [Abstract][Full Text] [Related]
10. Lipoxygenase metabolism: roles in tumor progression and survival. Pidgeon GP; Lysaght J; Krishnamoorthy S; Reynolds JV; O'Byrne K; Nie D; Honn KV Cancer Metastasis Rev; 2007 Dec; 26(3-4):503-24. PubMed ID: 17943411 [TBL] [Abstract][Full Text] [Related]
11. SPARC in cancer biology: its role in cancer progression and potential for therapy. Tai IT; Tang MJ Drug Resist Updat; 2008 Dec; 11(6):231-46. PubMed ID: 18849185 [TBL] [Abstract][Full Text] [Related]
12. Targeting TGFbeta-mediated processes in cancer. Romano MF Curr Opin Drug Discov Devel; 2009 Mar; 12(2):253-63. PubMed ID: 19333871 [TBL] [Abstract][Full Text] [Related]
13. Mitochondria and cancer chemoresistance. Guerra F; Arbini AA; Moro L Biochim Biophys Acta Bioenerg; 2017 Aug; 1858(8):686-699. PubMed ID: 28161329 [TBL] [Abstract][Full Text] [Related]
14. Mitochondriotoxic compounds for cancer therapy. Fantin VR; Leder P Oncogene; 2006 Aug; 25(34):4787-97. PubMed ID: 16892091 [TBL] [Abstract][Full Text] [Related]
15. Intracellular signal transduction pathway proteins as targets for cancer therapy. Adjei AA; Hidalgo M J Clin Oncol; 2005 Aug; 23(23):5386-403. PubMed ID: 15983388 [TBL] [Abstract][Full Text] [Related]
16. Overview of novel anticancer drug targets. Buolamwini JK; Assefa H Methods Mol Med; 2003; 85():3-28. PubMed ID: 12710193 [No Abstract] [Full Text] [Related]
19. Cancer destruction in vivo through disrupted energy metabolism. Part III. Spontaneous drug resistance, selectivity of antineoplastic action, and strategies for intensifying tumor injury. Jones GR Physiol Chem Phys Med NMR; 1992; 24(3):195-212. PubMed ID: 1461933 [TBL] [Abstract][Full Text] [Related]
20. The role of phosphatidylinositol 3-kinase signaling pathways in pancreatic cancer. Sun C; Rosendahl AH; Andersson R; Wu D; Wang X Pancreatology; 2011; 11(2):252-60. PubMed ID: 21625196 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]